Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 951 with chemotherapy ± bevacizumab in previously untreated advanced NSCLC
2005-005484-28Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dulanermin in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Incidence of dose-limiting toxicities (DLTs). Started Mar 2006; status: completed.
02
Drugs
dulanermin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005484-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005484-28.